SCHEMBL5189013

SCHEMBL5189013

CN1C(=O)CN(Cc2ccc(C(=O)O)cc2)C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 9/20 0.50
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 2/20 0.47
POLB P06746 2/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.47
THRB P10828 2/20 0.47
RECQL P46063 2/20 0.47
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
NR4A1 P22736 1/20 0.47
APEX1 P27695 1/20 0.47
APOBEC3A P31941 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
PTGS1 P23219 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5189032 0.84 HDAC6 (0.52) HDAC6MEN1GAAMAPTKMT2A
SCHEMBL7212064 0.82 ENPP2 (0.53) HDAC6ALDH1A1MEN1POLBMAPT
SCHEMBL838675 0.80 ENPP2 (0.43) HDAC6MEN1KMT2AENPP2HDAC1
SCHEMBL10938820 0.76 HDAC6 (0.72) HDAC6ALDH1A1MEN1POLBGAA
SCHEMBL13924881 0.75 ALDH1A1 (0.46) ALDH1A1MEN1MAPTRECQLKMT2A
SCHEMBL13924882 0.75 CHKA (0.49) ALDH1A1MEN1GAAMAPTKMT2A
SCHEMBL6705934 0.74 HDAC6 (0.42) HDAC6ALDH1A1HDAC1HDAC2HDAC8
SCHEMBL2774412 0.73 L3MBTL1 (0.66) HDAC6ALDH1A1MEN1POLBGAA
SCHEMBL1254047 0.72 L3MBTL1 (0.69) HDAC6ALDH1A1MEN1POLBGAA
SCHEMBL8360734 0.72 CYP2C9 (0.55) ALDH1A1MEN1GAAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279576-B2 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-10-09 US disclosed
US-7279576-B2 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-10-09 US disclosed
US-7279576-B2 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-10-09 US disclosed
EP-1590344-A4 ANTI-CANCER MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2007-08-29 EP disclosed
EP-1590344-A2 ANTI-CANCER MEDICAMENTS Deciphera Pharmaceuticals, Inc. (US) 2005-11-02 EP disclosed
US-20040176395-A1 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC 2004-09-09 US disclosed
WO-2004060305-A2 ANTI-CANCER MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176395-A1 Anti-cancer medicaments ABL1, ABL2, SRC HDAC6 713/4885ALDH1A1 1475/4885MEN1 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.